Could Combining Strategies Be A Way Forward To Pay For Gene Therapies?

A report by ICER and Tufts Medical Center’s NEWDIGS said a single strategy cannot adequately address payment challenges for all payers.

• Source: Shutterstock

With the number of US Food and Drug Administration-approved gene therapies set to balloon from fewer than 20 to about 100 by the early 2030s, the challenges of paying for them are bound to balloon as well, with total list-price spending potentially equivalent to the gross domestic products of some small countries. A recent report on the reimbursement models for gene therapies by the Institute for Clinical and Economic Review (ICER) and Tufts Medical Center’s NEWDIGS looks at the potential to combine strategies like reinsurance and rebates.

Pricing watchdog group ICER collaborated with Tufts Medical Center’s NEWDIGS (New Drug Development Paradigms) – an outcomes research-focused think tank...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More from Advanced Therapies

Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

 
• By 

The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.